The United Laboratories International Holdings Limited (HKG:3933)
Hong Kong · Delayed Price · Currency is HKD 15.94
-0.10 (-0.62%)
Sep 18, 2025, 1:45 PM HKT
HKG:3933 Revenue
The United Laboratories International Holdings had revenue of 7.52B CNY in the half year ending June 30, 2025, with 8.86% growth. This brings the company's revenue in the last twelve months to 14.10B, up 0.66% year-over-year. In the year 2024, The United Laboratories International Holdings had annual revenue of 13.76B with 0.14% growth.
Revenue (ttm)
14.10B CNY
Revenue Growth
+0.66%
P/S Ratio
2.05
Revenue / Employee
829.52K CNY
Employees
17,000
Market Cap
31.65B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13.76B | 19.06M | 0.14% |
| Dec 31, 2023 | 13.74B | 2.41B | 21.22% |
| Dec 31, 2022 | 11.33B | 1.63B | 16.81% |
| Dec 31, 2021 | 9.70B | 930.95M | 10.61% |
| Dec 31, 2020 | 8.77B | 379.89M | 4.53% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 35.81B |
| JD Health International | 71.34B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |
| Sino Biopharmaceutical | 33.49B |
| WuXi Biologics | 21.98B |
| Akeso | 2.75B |
| CSPC Pharmaceutical Group | 28.49B |
The United Laboratories International Holdings News
- 6 months ago - Novo Nordisk Strikes $2B Deal for Obesity Drug - Investopedia